Justin Taylor, MD
Chronic Lymphocytic Leukemia (CLL); Hairy Cell Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS)
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Accepted Insurance Providers
Dr. Taylor accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral.
Blue Cross Blue Shield
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- The Empire Indemnity Plan provides limited coverage for our services.
Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
EmblemHealth (including GHI, HIP, ConnectiCare, and Vytra)
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, and HMO plans as well as their Enhanced Care Prime Network, which supports Medicaid Managed Care and Child Health Plus and Medicare plans. Memorial Sloan Kettering is also in-network with the New York State Essential Emblem Health plan, which can be purchased on the insurance exchange. Emblem Health does not include us in any of its Medicare plans or in any of its Select Care network plans. You must bring a referral from your Emblem primary care doctor to your first appointment.
Empire Blue Cross Blue Shield Health Plus
Formerly known as Health Plus Amerigroup, Empire Blue Cross Blue Shield Health Plus is an in-network provider with Memorial Sloan Kettering. You will need a one-time referral from your primary care doctor.
Health Insurance Exchanges
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We're here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Interlink Health Services
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
New York State Medicaid covers physician and hospital services at Memorial Sloan Kettering. Patients are responsible for co-payments.
We also have contractual relationships involving Medicaid Managed Care plans. MSK is an in-network provider with Medicaid NY Emblem Health (formerly known as HIP) and Medicaid NY Empire Blue Cross Blue Shield HealthPlus (formerly known as Amerigroup). You will need a one-time referral from your primary care doctor.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
Multiple Insurance Plans
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
New York State Employee Health Insurance Plan (Empire Plan)
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar's Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Other Coverage Options
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford's Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Specialty Care Management
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
World Trade Center Health Program
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Contact and Location
Find a Convenient Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.
MD, University of New Mexico
Internal Medicine - Brigham and Women’s Hospital of Harvard Medical School
Medical Oncology - Memorial Sloan Kettering Cancer Center
Internal Medicine; Medical Oncology
I am a medical oncologist who specializes in treating leukemia and myelodysplastic syndromes. I have a strong interest in caring for people who have rare forms of these diseases. I also have expertise in early-phase clinical trials of targeted therapies for these illnesses. I help my patients participate in these research studies when they are eligible.
I decided to pursue a career in oncology because I saw the need to develop better-tolerated and more-effective treatments for people with cancer. That’s why I am also a scientist investigating how normal cells become cancerous and how we can target that process with precision therapies.
My research focuses on finding mutations that occur in chronic lymphocytic leukemia and hairy cell leukemia. My goal is to develop new treatments for these diseases. I am also working on a trial to test a drug that would treat specific types of mutations, called splicing factor mutations. They are present in people with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML). Our research helped lead to FDA approval of a breakthrough new treatment, called enasidenib (Idhifa®), for AML that has stopped responding to other therapies. We found that people who received this drug had higher response rates and lived longer than people who received existing treatments.
When I meet with patients, it’s my goal that they leave their visit feeling more knowledgeable about and comfortable with their treatment plan than when they walked through the door. We’ll spend as much time together as needed to make sure this happens.
Awards and Honors
- American Society of Clinical Oncology Young Investigator Award (2017)
- American Society of Hematology Medical Faculty Development Program (2017)
- Hairy Cell Leukemia Foundation Fellowship Program (2017)
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials Co-Investigated by Dr. Taylor
- A Phase I/II Study of LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Find a Clinical Trial for You
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. The Journal of clinical investigation. 2018; 128(9):3819-3825. PubMed [journal] PMID: 29920189 PMCID: PMC6118587
Lee SC, North K, Kim E, Jang E, Obeng E, Lu SX, Liu B, Inoue D, Yoshimi A, Ki M, Yeo M, Zhang XJ, Kim MK, Cho H, Chung YR, Taylor J, Durham BH, Kim YJ, Pastore A, Monette S, Palacino J, Seiler M, Buonamici S, Smith PG, Ebert BL, Bradley RK, Abdel-Wahab O. Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer cell. 2018; 34(2):225-241.e8. PubMed [journal] PMID: 30107174
Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia. 2018; PubMed [journal] PMID: 30038380
Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud N, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB, Levine RL, Stein EM. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018; 559(7712):125-129. NIHMSID: NIHMS964938 PubMed [journal] PMID: 29950729 PMCID: PMC6121718
Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nature medicine. 2018; 24(4):497-504. PubMed [journal] PMID: 29457796
Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017 Jul 27;130(4):410-423. PubMed PMID: 28600336; PubMed Central PMCID: PMC5533199.
Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, Krivtsov A, Armstrong SA, Palacino J, Buonamici S, Smith PG, Bradley RK, Abdel-Wahab O. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016 Jun;22(6):672-8. PubMed PMID: 27135740; PubMed Central PMCID: PMC4899191.
Taylor J, Kim SS, Stevenson KE, Nori A, Kopp N, Louissaint A, Harris N, Hochberg EP, Chen Y, Lovitch SB, DeAngelo DJ, Wadleigh M, Steensma DP, Motyckova G, Stone RM, Neuberg DS, Jardin F, Piccaluga P, Weinstock DM, Lane AA. Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance. Blood. 122(21).
Durham BH, Getta B, Dietrich S, Taylor J, Won H, Bogenberger JM, Scott S, Kim E, Chung YR, Chung SS, Hüllein J, Walther T, Wang L, Lu SX, Oakes CC, Tibes R, Haferlach T, Taylor BS, Tallman MS, Berger MF, Park JH, Zenz T, Abdel-Wahab O. Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood. 2017 Aug 11;PubMed PMID: 28801450.
Taylor J, Abdel-Wahab O. Hematology. 7th ed. Hoffman R, editor. Philadelphia: Elsevier; Chapter 10, Stem Cell Model of Hematologic Diseases2408p.